This online educational activity, titled Redefining the Role of Anthracyclines in Contemporary Breast Cancer Management, contains video and downloadable slides focusing on clinical data surrounding the use of anthracyclines for the treatment of breast cancer and important factors to improve patient outcomes. |
|
FACULTY | Chair
Antonio Llombart Cussac, MD, PhD
Hospital Universitario Arnau de Vilanova
Valencia, Spain
Faculty
Peter Schmid, MD, PhD
Brighton & Sussex Medical School
Brighton, United Kingdom
Guenther Steger, MD
Medical University of Vienna
Vienna, Austria
Giuseppe Viale, MD, FRCPath
European Institute of Oncology
and the University of Milan
Milan, Italy
|
Target Audience | This activity is specifically designed for European medical oncologists, surgical and radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with breast cancer. This meeting is restricted to healthcare professionals based in Europe. |
|
|
 |
|
Expert Discussion
|
 |
|
Downloadable Slides
|
|
 |
|
TOPICS | The role of nonpegylated liposomal doxorubicin in combination therapy for metastatic breast cancer (MBC)
Peter Schmid, MD, PhD
Emerging neoadjuvant strategies for HER2-positive breast cancer
Antonio Llombart Cussac, MD, PhD
Factors influencing therapeutic decisions for MBC: The European
The European Observatory & Survey (EOS) Study
Guenther Steger, MD
The importance of accurate HER2 testing in breast cancer clinical trials
Giuseppe Viale, MD, FRCPath |
LEARNING OBJECTIVES | Upon completion of this educational activity, participants should be able to:
- Describe the role of anthracyclines in the management of breast cancer
- Discuss strategies to optimize treatment for patients with breast cancer
|
|
|
|
Organizer | This meeting is a prIME Oncology activity.
|
Support | Support for this educational activity is provided by Cephalon Europe.
|
|
